B
Brian I. Rini
Researcher at Vanderbilt University Medical Center
Publications - 652
Citations - 49231
Brian I. Rini is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 89, co-authored 608 publications receiving 38953 citations. Previous affiliations of Brian I. Rini include University of California, San Francisco & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
Yoshihiko Tomita,Robert J. Motzer,T. Choueiri,Brian I. Rini,Hideaki Miyake,Hirotsugu Uemura,Laurence Albiges,Yoritaka Fujii,Yoshiko Umeyama,J Wang,Mario Mariani,Manuela Schmidinger +11 more
TL;DR: In this paper , avelumab plus axitinib and sunitiniband were compared in patients with advanced renal cell carcinoma (aRCC). But, efficacy in elderly patients remains unclear.
Journal ArticleDOI
TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Brian I. Rini,Sumanta K. Pal,Bernard Escudier,Michael B. Atkins,Thomas E. Hutson,Camillo Porta,Elena Verzoni,Michael N. Needle,David F. McDermott +8 more
TL;DR: T is superior to S as measured by PFS; 2-year PFS, and ORR in this pre-treated population and is better tolerated than S.
Journal ArticleDOI
Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.
David F. McDermott,Brian I. Rini,Robert J. Motzer,Nizar M. Tannir,Bernard Escudier,Christian Kollmannsberger,Hans J. Hammers,Camillo Porta,Saby George,Frede Donskov,Howard Gurney,Marc-Oliver Grimm,Michael R. Harrison,Thomas E. Hutson,Shuo Yang,Jennifer L. Johansen,Sumati Rao,Sabeen Mekan,Michael Rael,Thomas Powles +19 more
TL;DR: The durable TFS benefit across risk groups despite discontinuation of therapy provides further evidence of the encouraging benefit-risk profile of NIVO+IPI over SUN in pts with previously untreated aRCC.
Journal ArticleDOI
Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC)
Robert Dreicer,Jorge A. Garcia,S. Smith,Paul Elson,Pierre L. Triozzi,S. Hodnick,Brian I. Rini,E.A. Klein +7 more
TL;DR: A phase I safety phase followed by a phase II trial in pts with HRPC to evaluate the clinical and immune activity of GM-CSF plus lenalidomide and to date 19 of 34 planned pts are enro...
Journal ArticleDOI
Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients.
Kriti Mittal,Lisa Derosa,Laurence Albiges,Laura S. Wood,Paul Elson,Timothy D. Gilligan,Jorge A. Garcia,Robert Dreicer,Bernard Escudier,Brian I. Rini +9 more
TL;DR: Outcomes in patients receiving prolonged treatment breaks on TKIs demonstrate efficacy in mRCC, but may cause significant adverse effects (AEs) and expand and update this experience herein.